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Abstract
Background: The 14-3-3 test appears to be a valuable aid for the clinical diagnosis of sporadic
Creutzfeldt-Jakob disease (sCJD) in selected populations. However, its usefulness in routine
practice has been challenged. In this study, the influence of the clinical context on the performance
of the 14-3-3 test for the diagnosis of sCJD is investigated through the analysis of a large
prospective clinical series.
Methods: Six hundred seventy-two Spanish patients with clinically suspected sCJD were analyzed.
Clinical classification at sample reception according to the World Health Organization's (WHO)
criteria (excluding the 14-3-3 test result) was used to explore the influence of the clinical context
on the pre-test probabilities, and positive (PPV) and negative (NPV) predictive values of the 14-3-
3 test.
Results: Predictive values of the test varied greatly according to the initial clinical classification:
PPV of 98.8%, 96.5% and 45.0%, and NPV of 26.1%, 66.6% and 100% for probable sCJDi (n = 115),
possible sCJDi (n = 73) and non-sCJDi (n = 484) cases, respectively. According to multivariate and
Bayesian analyses, these values represent an improvement of diagnostic certainty compared to
clinical data alone.
Conclusion: In three different contexts of sCJD suspicion, the 14-3-3 assay provides useful
information complementary to clinical and electroencephalographic (EEG) data. The test is most
useful supporting a clinical impression, whilst it may show deceptive when it is not in agreement
with clinical data.
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Background
At present, the definitive diagnosis of sporadic Creut-
zfeldt-Jakob disease (sCJD) requires the neuropathologi-
cal examination of affected brain tissues. However, several
ancillary tests may add support to the clinical findings. In
particular, the identification of periodic sharp wave com-
plexes (PSWCs) in electroencephalographic (EEG) records
[1] and 14-3-3 protein in cerebrospinal fluid (CSF) [2]
have proved to be useful, and are included among current
diagnostic criteria [3].
The use of the 14-3-3 test for the diagnosis of prion dis-
eases was described in 1996 [2]. This protein is a reliable
marker of rapid neuronal destruction [4], and has been
detected in the CSF in several progressive neurological dis-
orders [2,5-7]. The performance of the 14-3-3 test has
been analyzed mainly on selected populations with pre-
defined patients and control groups, yielding sensitivity
and specificity values around 94% and 84%, respectively
[8]. However, the populations studied may not reflect the
real situation in clinical practice, and it is well known that
the parameters of sensitivity and specificity are less useful
for the clinicians than predictive values. We describe our
experience in a reference laboratory dedicated to assist
through molecular testing in the diagnosis of prion dis-
eases in Spain. In this cohort of suspected sCJD cases, we
have examined the performance of the 14-3-3 test and its
impact on diagnostic certainty through the analysis of the
predictive values in 3 different clinical contexts.
Methods
Patients and classification algorithm
All samples analyzed in this study were obtained from
patients with suspected prion diseases, submitted to our
laboratory for diagnostic purposes under the guidelines of
the Spanish National Referral and Surveillance system. No
healthy controls are included in the analysis. For this
study, all samples were coded and personal information
dissociated from the test results, according to local legisla-
tion at the time of analysis. This research does not include
identifiable human material or identifiable data. The
Bioethics and Animal Welfare Committee from the Insti-
tuto de Salud Carlos III (Spanish Ministry of Health) eval-
uated this research work and granted a positive opinion
stating that the work conformed the Helsinki Declaration
and local legislation (Minutes from the April 18th, 2006
meeting).
The population under study included patients with sus-
pected prion diseases, whose CSF samples were submitted
to our laboratory from January 1997 to December 2003.
Spain countrywide-patients were analyzed. Cloudy,
bloodstained, or hemolytic CSF samples were excluded
from the analysis (Figure 1). In order to avoid false-posi-
tive 14-3-3 results from slightly hematic/hemolytic sam-
ples (not perceptible by eye inspection), we checked the
hemoglobin content of each sample by Combur strip test
(Combur10 Test M, Roche). Samples yielding hemo-
globin signals equivalent to 250 erythrocytes/µl or higher
were not analyzed. We applied World Health Organiza-
tion's criteria (WHO's criteria) (Table 1, see ref. [3])
excluding the 14-3-3 test results in order to obtain an ini-
tial and a final classification of each case; hereafter denoted
by subscripts "i" or "f" at the end of the classificatory term
(i.e. sCJDi or sCJDf).
For the purpose of analysis, initial classification was based
on clinical records at the time of sample reception before
the performance of the 14-3-3 test. Patients initially fulfill-
ing WHO's criteria were classified either as possible sCJDi
or probable sCJDi, while the rest of cases were classified as
non-sCJDi.
Final classification of patients was accomplished by obtain-
ing and reviewing detailed clinical, epidemiological, and
neuropathological information through a structured
questionnaire sent by hospital personnel, and exhaustive
follow-up contact with the referring physicians and the
Spanish National Human Transmissible Spongiform
Encephalopathies Registry [9]. Patients finally fulfilling
WHO's criteria (without 14-3-3 test results) were classi-
fied as definite sCJDf or probable sCJDf, while the remain-
ing patients were classified as non-sCJDf cases. Since one
of the main aims of this study was the analysis of the pre-
dictive values of the 14-3-3- test in a real practice situa-
tion, both definite and probable sCJDf  cases at final
diagnosis were considered as gold standard.
The classification algorithm applied to our population is
depicted in Figure 1. During the 7-year period covered by
the study, we received 830 CSF samples. Patients with
hematic/hemolytic CSF samples, insufficient clinical
information, genetic etiology, or possible sCJDf at final
classification were excluded. Overall, 672 patients quali-
fied for the study (Figure 1). The initial classification of
these patients at the time of sample reception according to
WHO's criteria excluding the 14-3-3 test protein included
73 possible sCJDi, 115 probable sCJDi, and 484 non-
sCJDi. Final classification of these patients encompassed
75 definite sCJDf (pathologically confirmed), 102 proba-
ble sCJDf, and 495 non-sCJDf cases (patients pathologi-
cally excluded, showing a clinical course not compatible
with prion disease or with alternative diagnoses).
Analysis of the polymorphism at codon 129 of PRNP gene
Genomic DNA was directly extracted from peripheral
blood with DNAzol Genomic DNA Isolation Reagent
(Molecular Research Center, Inc.), according to the man-
ufacturer's instructions. The coding region of PRNP gene
was amplified by PCR. The polymorphism at codon 129BMC Neurology 2006, 6:25 http://www.biomedcentral.com/1471-2377/6/25
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was examined either by restriction enzyme digestion with
NspI or by DNA sequencing of the amplicons.
Demographic and clinical data
In this series of 672 patients, sCJDf (definite and proba-
ble) and non-sCJDf cases had similar gender distribution
and age at onset: sCJDf (94/177 females, median age 70.4
y, SD 8.4 y, range 45.1–86.9 y) vs. non-sCJDf (232/495
females, median age 69.1 y, SD 12.9, range 27.9–81.7 y).
The three most frequent symptoms among sCJDf cases
were dementia, myoclonus and cerebellar signs (Figure
2). The distribution of the polymorphisms at codon 129
was 69.5% 129MM, 16.1% 129MV, and 14.4% 129VV for
sCJDf (n = 118), and 43.6% 129MM, 44.3% 129MV, and
12.1% 129VV for non-sCJDf (n = 289).
14-3-3 test
The presence of 14-3-3 protein in CSF was analyzed by the
method previously described [2] with minor modifica-
tions [10]. Briefly, proteins in 20 µl CSF were mixed with
15 µl of Laemmli buffer (2x) containing 0.1 M dithiothre-
itol (Bio-Rad) and solubilized at 100°C for 5 minutes.
Proteins were then separated by electrophoresis in sodium
dodecyl sulfate-polyacrylamide gels (4% stacking, 12%
separating) and transferred to nitrocellulose membranes
(Amersham, Biosciences). Immunostaining was per-
formed after membrane blocking (Super Block, Pierce) by
overnight incubation at room temperature with an anti
14-3-3β polyclonal rabbit antibody (sc-629, Santa Cruz
Biotecnology). The 14-3-3 antigens were detected with
alkaline phosphatase conjugated to goat anti-rabbit IgG
Diagnostic and classification algorithm applied to our series of clinically suspected sCJD cases Figure 1
Diagnostic and classification algorithm applied to our series of clinically suspected sCJD cases.
See table 4
See table 2
Initial 
Classification
Final 
Classification
Final 
Classification
Final 
Classification
Final 
Classification
Samples qualified for the analysis 
All patients (n=672)
CSF samples received from 
suspected CJD patients (n=830) 
(1997-2003)
Excluded (n=158)
-Hemolytic CSF (n=78)
-Genetic etiology (n=11)
-Insufficient follow-up information (n=55)
-Possible sCJD at final classification (n=14)
Probable sCJDi (n=115)
Possible sCJDi (n=73)
Non-sCJDi (n=484)
• Definite sCJDf (n=4)
• Probable sCJDf (n=5)
• Non-sCJDf (n=475)
• Definite sCJDf (n=75)
• Probable sCJDf (n=102)
• Non-sCJDf (n=495)
• Definite sCJDf(n=43)
• Probable sCJDf (n=64)
• Non-sCJDf (n=8)
• Definite sCJDf (n=28)
• Probable sCJDf (n=33)
• Non-sCJDf (n=12)BMC Neurology 2006, 6:25 http://www.biomedcentral.com/1471-2377/6/25
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and developed by colorimetric reaction with NBT/BCIP
(Pierce Biotechnology, Inc). The immunoreactivity of
each sample at the 30 kDa. band was assessed by two dif-
ferent observers blinded to the clinical data, in at least two
different experiments. According to the presence or
absence of immunoreactivity at the 30 kDa. band, sam-
ples were classified as negative or positive. As the test is
based on a semiquantitative technique, some samples
could not be clearly classified as negative or positive com-
pared to reference standards that included a positive con-
trol from a sCJD patient and a weakly positive control
sample from a non-CJD patient. For the purpose of this
study and the diagnostic service provided to clinicians,
trace samples with immunoreactivity lower than the
weakly positive control sample were considered negative
(see discussion).
Statistical analysis
Univariate comparisons between groups were performed
with the χ2 and Mann-Whitney tests, as appropriate. Mul-
tivariate logistic regression analysis was performed taking
the final diagnosis as dependent variable (sCJDf /non-
sCJDf) and the clinical, EEG and 14-3-3 protein data as
covariates. Bayesian analysis was performed calculating
the positive (LR+) and negative (LR-) likelihood ratio sta-
tistics. The multivariate and Bayesian analyses were lim-
ited to definite sCJDf and non-sCJDf. All the statistical
calculations were performed with SPSS software.
Results
Performance of the 14-3-3 test
The prevalence of sCJDf (definite and probable) in the
overall cohort of suspected cases (n = 672) was 26.3%.
The performance parameters of the 14-3-3 test are shown
in Table 2. The efficiency of the test, i.e. the proportion of
subjects correctly classified, was 94.5%. Among sCJDf
patients, no statistically significant differences were found
between 14-3-3-positive and 14-3-3-negative cases for any
of the parameters studied (Table 3). However, a tendency
to a later onset and longer duration of disease was
observed among 14-3-3-negative sCJDf patients, as previ-
ously described [11], and in agreement with the higher
sensitivity observed in classic sCJD cases compared with
non-classical presentations [12].
Influence of the clinical context on the 14-3-3 test
Table 4 summarizes the performance of the test in three
categories of patients classified upon sample reception
according to WHO's criteria excluding 14-3-3 test results.
The prevalence of sCJDf within the probable sCJDi sub-
group (n = 115) was 93.0%. Ninety sCJDf were 14-3-3-
positive, and the remaining 17 cases were false-negatives
(7 definite and 10 probable sCJDf cases). Two false-posi-
Table 2: Contingency table and performance values of the 14-3-3 
test in a population of clinically suspected sCJD cases
All cases, n = 672
Final diagnosis sCJDf non-sCJDf
14-3-3 result Pos. 155 [67] 15
Neg. 22 [8] 480
Performance values (%)
PPV 91.2 (85.6–94.8)
NPV 95.6 (93.3–97.2)
Sensitivity 87.6 (81.6–91.9)
Specificity 96.9 (94.9–98.2)
Efficiency 94.5 (92.5–96.0)
Prevalence 26.3 (23.2–29.8)
sCJDf includes both probable (WHO's criteria without the inclusion 
of the 14-3-3 test results) and definite cases at final diagnosis. Definite 
cases are shown in square brackets. Confidence intervals at 95% level 
are shown in parentheses.
Table 1: World Health Organization's criteria for the 
classification of sCJD
I. Rapidly progressive dementia
II. A. Myoclonus
B. Visual or Cerebellar problems
C. Pyramidal or extrapyramidal features
D. Akinetic mutism
III. A. Typical EEG
B. Positive 14-3-3
Possible sCJD: I and 2 of II and duration less than 2 years
Probable sCJD: I and 2 of II and IIIA or possible CJD and IIIB
Definite sCJD: Neuropathologically/immunocytochemically 
confirmed
Frequency of clinical and paraclinical data in sCJDf (light  shaded bars) and non-sCJDf patients (dark shaded bars) Figure 2
Frequency of clinical and paraclinical data in sCJDf 
(light shaded bars) and non-sCJDf patients (dark 
shaded bars). * p < 0.05, ** p < 0.01, and *** p < 0.001. 
sCJDf includes both probable and definite patients.
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tive cases met diagnostic criteria for probable sCJDi, but
were finally diagnosed as vascular dementia. These two
false-positive patients showed rapidly progressive demen-
tia, myoclonus, visual disturbances, and PSWCs. Within
this group, 6 patients initially fulfilled sCJD criteria and
displayed PSWCs, but finally were classified as non-sCJD
cases. Four of these patients were confirmed as alternative
diagnoses by post-mortem examination and included 2
patients with a neurological paraneoplastic syndrome,
one patient with Lewy body dementia, and one patient
with toxic encephalopathy; the remaining two patients
after prolonged course of the disease did not meet criteria
for CJD and were classified by the referring clinicians as
probable Alzheimer's disease and Lewy body dementia
(disease duration > 3 years), respectively. In the category
of possible sCJDi (n = 73 cases), the prevalence of sCJDf
was 83.6%. Twelve patients were later reclassified as non-
sCJDf. There were two false-positive cases: one with defi-
nite Lewy Body dementia, and one with vascular demen-
tia. Five 14-3-3-negative patients were finally classified as
sCJDf. Within this group, 5 patients gave false negative
results, and included one patient confirmed as sCJD at
post-mortem examination and 4 patients that showed
PSWCs later along the course of their disease.
Within the category of non-sCJDi (n = 484), the preva-
lence of sCJDf was 1.9%. All cases classified as definite
sCJDf (n = 4) or probable sCJDf (n = 5) had a 14-3-3-pos-
itive test. The four definite sCJDf cases never showed
PSWCs, and two of them did not display dementia at
onset. The other five probable sCJDf  cases developed
dementia and their EEG became typical at a later stage of
disease once the 14-3-3 analysis had been performed. The
14-3-3 test also yielded 11 false-positive results that never
fulfilled clinical criteria for sCJD. Interestingly, there were
no false-negative results when the initial diagnosis was
non-sCJDi.
Table 4: Contingency tables and performance of the 14-3-3 test according to the initial clinical classification
Initial diagnosis
Probable CJD,i n= 115 Possible CJD,i n= 73 non-sCJD,i n= 484
Final diagnosis sCJDf non-sCJDf sCJDf non-sCJDf sCJDf non-sCJDf
14-3-3 result Pos. 90 [36] 2 56 [27] 2 9 [4] 11
Neg. 17 [7] 6 5 [1] 10 0 464
Performance values (%)
PPV 97.8 (91.6–99.6) 96.5 (87.0–99.4) 45.0 (23.8–68.0)
NPV 26.1 (11.1–48.7) 66.6 (38.7–87.0) 100 (99.0–100.0)
Sensitivity 84.1 (75.5–90.2) 91.8 (81.2–96.9) 100 (62.9–100.0)
Specificity 75.0 (35.5–95.5) 83.3 (50.9–97.1) 97.7 (95.8–98.8)
Efficiency 83.5 (75.6–89.3) 90.4 (81.3–95.6) 97.7 (95.9–98.8)
Prevalence 93.0 (86.7–96.7) 83.6 (73.3–90.5) 1.9 (0.9–3.6)
sCJDf includes both probable (WHO's criteria without the inclusion of the 14-3-3 test results) and definite cases at final diagnosis. Definite cases are 
shown in square brackets. Confidence intervals at 95% level are shown in parentheses.
Table 3: Age at onset, survival time, lumbar puncture (LP) timing, presence of PSWCs in EEG, and genotype at codon 129 of PRNP 
gene of 14-3-3-positive and 14-3-3-negative sCJDf patients
14-3-3 result Age at onset, 
years
Survival time, 
months
Time from 
onset to LP, 
months
Time from LP 
to death, 
months
PSWCs in EEG, 
%
M129V, %
Positive 69.8 (45.1–86.9), 
n= 144
4.7 (0.5–48.8), 
n= 138
2.6 (0.7–27.2), 
n= 125
1.2 (0–30.8),
 n= 119
83.9%, 
n= 112
68.0%MM, 
15.5%MV, 
16.5%VV, n= 103
Negative 73.4 (59.1–82.3), 
n= 21
5.4 (0.4–29.9),
 n= 15
2.9 (0.2–13.9), 
n= 17
1.3 (0–26.8), n= 14 81.8%, n= 22 80.0%MM, 
20.0%MV, 0%VV, 
n= 15
sCJDf includes both probable and definite cases. The data of age, survival time, and LP timing correspond to median and range values.BMC Neurology 2006, 6:25 http://www.biomedcentral.com/1471-2377/6/25
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Improving diagnostic accuracy
Univariate analyses comparing patients with final diag-
noses of probable or definite sCJDf versus non-sCJDf cases
showed, as expected, that myoclonus, pyramidal signs,
akinetic mutism, as well as PSWCs, 14-3-3 positive result,
and homozygosis at codon 129, were all associated with
sCJD. In order to explore whether the 14-3-3 test provide
information of diagnostic relevance when added to
WHO's criteria, we applied multivariate analysis and
Bayesian statistics. For definite cases, multivariate analysis
including the clinical, and the EEG or the 14-3-3 data in
two separate models, showed that the only predictive fac-
tors for sCJD were myoclonus (OR: 9.4; 95% CI: 1.2–
70.9), akinetic mutism (OR: 16.4; 95% CI: 1.5–202.5),
PSWCs (OR: 5.8; 95% CI: 1.5–21.9), and positive 14-3-3
test (OR: 146.5; 95% CI: 15.1–1415.6).
According to Bayesian analysis, the LR+ for WHO's criteria
alone was 23.4 (95 % CI: 15.2–36.1) and LR- was 0.06 (95
% CI: 0.02–0.14). The LR+ for the 14-3-3 test alone was
29.5 (95 % CI: 17.8–48.8) and the LR- was 0.11 (95 % CI:
0.06–0.21). The LR+ and LR- for combined WHO's crite-
ria and 14-3-3 test were 103.9 (95 % CI: 39.0–277.2) and
0.2 (95 % CI: 0.1–0.3), respectively. These results indicate
that the inclusion of the 14-3-3 test produces a moderate
but significant increase in the LR+ compared to WHO's
criteria alone. In other words, given a pre-test probability
of disease in our cohort of 13.2% (prevalence of sCJDf
restricted to definite cases), after applying WHO's criteria
alone, the PPV among patients that fulfilled criteria was
78.0%, while the NPV was 99.2%. Considering the 14-3-
3 test alone, the PPV was 81.7%, while the NPV was
98.4%. When both analyses were combined as serial tests,
the PPV for patients that fulfilled criteria and had a 14-3-
3 result was 94.0%, while the NPV for patients that neither
fulfilled criteria nor had a positive 14-3-3 result was
100%.
Discussion
Since the introduction of the 14-3-3 test for the diagnosis
of sCJD [2], the test has been shown to be feasible, reliable
and valid under controlled conditions, and it is therefore
now routine practice in the diagnostic workup of sus-
pected CJD patients. According to published results, the
sensitivity and specificity of the test are about 93% and
84%, respectively [8]. PPV and NPV are highly dependent
on the population tested, and are consequently relevant
only when applied within similar clinical contexts. More-
over, the importance of the "context of suspected sCJD"
has been emphasized but not defined [8]. In this study, we
have followed prospectively a series of 672 patients with a
clinical suspicion of sCJD, whose samples were submitted
for evaluation to our laboratory according to the guide-
lines of the Spanish National Health System. The analysis
of this series provides an operational frame for classifica-
tion and definition of such context of suspected sCJD.
This context, linked to the interpretation of 14-3-3 test
results, has not yet been empirically illustrated in large
series of patients. Unfortunately, the large EUROCJD
(European and Allied Countries Collaborative Study
Group of CJD) research database, generated mainly for
surveillance, is useful for evaluation of sensitivity and spe-
cificity, but it does not contain information on controls
free from human transmissible spongiform encephalopa-
thies.
The use of three subgroups of patients classified according
to WHO's criteria at sample reception is operationally fea-
sible; although it requires access to EEG results for 14-3-3
test interpretation. Our own results suggest that a positive
14-3-3 test in a patient with possible or probable sCJDi at
initial classification is nearly always a true positive, whilst
a negative test in a low-risk individual is almost certainly
a true negative. In contrast, a negative result in a patient
initially classified as possible or probable sCJDi should
not rule out the diagnosis, and a positive test in a low-risk
patient could be a false positive. In summary, the 14-3-3
assay is most useful supporting a clinical suspicion, but it
may show deceptive when it is not in agreement with clin-
ical data. In the three subgroups the PPV lay above their
respective sCJD prevalence, indicating that the test pro-
vided useful information complementary to the clinical
and EEG data. This observation was further supported by
multivariate and Bayesian analyses.
Recently, Huang and collaborators [13] investigated the
performance of the 14-3-3 test in a series of patients with
rapidly progressive dementia. They concluded that the 14-
3-3 test might not differentiate CJD from other rapidly
progressive dementias. Similar results were previously
found by Burkhard and collaborators [6] in patients with
unselected dementia, since the PPV for this group was low
(28%, 95% CI: 7%–40%). Geschwind and collaborators
[14] also challenged the utility of the 14-3-3 test after find-
ing a modest sensitivity in their retrospective analysis of
32 definite sCJD cases. In the same line, more recently,
Blennow and collaborators have reported low sensitivity
(44%) and PPV (36%) values for a small cohort (n = 36)
of clinically suspected CJD [15], suggesting that method-
ological differences are responsible for the diverse results
described in the literature. The risks of the indiscriminate
use of the 14-3-3 test have been also pointed out by other
authors [6]. Our results on the interpretation of the test
shed light on these discrepancies and indicate that clinical
profile should be thoroughly evaluated at sample recep-
tion, when the test would be most useful in clinical deci-
sion-making.
Analysis of our series indicated slightly lower sensitivity
and higher specificity values than those previouslyBMC Neurology 2006, 6:25 http://www.biomedcentral.com/1471-2377/6/25
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described [2,11]. In our opinion, these differences con-
cern mainly the interpretation of trace results, and the
presence of small amounts of blood contaminating the
CSF samples. The 14-3-3 determination in CSF by immu-
noblotting implies some difficulties for the interpretation
of trace results, i.e. those that are neither clearly negative
nor positive. We have interpreted trace results as negative.
This practice avoids the exclusion of other potentially
treatable diseases, since a 14-3-3 positive result might be
interpreted by the clinician as a confirmation of the clini-
cal suspicion of this so far untreatable disease. On the
other hand, this strategy increases the number of false-
negative results that according to other authors pose an
important risk due to the transmissibility of the disease
and the potential hazards derived from patient care and
sample manipulation [14]. However, as we have presently
discussed, a negative result in a patient with high clinical
suspicion does not exclude the diagnosis of sCJD. Further-
more, our strategy allows optimizing the PPV of the test.
The second reason for discrepancy might be related to
blood contamination of samples. In our hands, a small
percentage of samples were contaminated by blood at lev-
els undetectable by eye inspection, but sufficient to pro-
duce false-positives due to the presence of serum proteins
in the CSF (data not shown). Accordingly, samples yield-
ing hemoglobin levels equivalent to more than 250 eryth-
rocytes/µl were excluded. The inclusion of this pre-test
analysis allowed us to increase the specificity of the 14-3-
3 test by rejecting potential false-positive samples.
Our study has several features of clinical relevance. Firstly,
it is a prospective analysis of all sCJD suspected patients,
and accordingly is not circumscribed to a subset of defi-
nite and control cases. Therefore, it represents a real prac-
tice situation and allows the estimation of predictive
values of relevance for clinical decision-making. Secondly,
it includes a large sample of patients attended by many
physicians at a variety of institutions, which increases the
external validity of the study. Thirdly, the period of obser-
vation spanned 7 years, long enough to obtain full follow-
up information from most sCJD cases. Finally, the 14-3-3
test was performed and interpreted by a limited team
using standardized techniques, which reduces the inter-
rater variability of the test. Unfortunately, our study has
also several limitations. Most important, we still have a
low rate of autopsies of 41.5%, and we do not know the
PrPSc  isoform in a sufficient number of cases to be
included in this study. Moreover, we also had a significant
number of losses from insufficient follow-up. These cases
always raise concerns about their possible peculiarities
(e.g. long duration 129VV homozygotes) [16], and the
consequent biases derived from their exclusion.
The implementation of quantitative protocols for the
determination of 14-3-3 protein in CSF [17,18], together
with the determination of other biological markers and
EEG and MRI data, all of them considered in the particular
clinical context of each patient, might result in the near
future into the development of protocols with high pre-
dictive values for the in vivo diagnosis of sCJD.
Conclusion
In conclusion, this work helps to define the concept of
clinical context for the correct use and interpretation of
the 14-3-3 test. Our results demonstrate that the combina-
tion of clinical classification at the time of test perform-
ance together with the results of the 14-3-3 test provides
physicians with a valuable diagnostic aid.
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